1. subjects with any of the following conditions that would impair their ability to participate reliably in the trial, or those who may increase the risk to themselves or others by participating 1. clinically significant laboratory abnormalities (including a screening test of aspartate aminotransferase/alanine aminotransferase (ast/alt) \> 5 times the upper limit of normal \[uln\] and/or estimated glomerular filtration rate \[egfr\] \< 30 ml/min/1.73m2) 2. serious medical illnesses (including known history of major hematological, renal, cardiovascular, or hepatic abnormalities that are clinically significant) 3. psychological condition or social circumstances 2. received an experimental medication within 1 month prior to screening or expect to receive such treatment during the study period. 3. with contraindication or hypersensitivity to the study product or any of its component. 4. pregnant or lactating women. 5. unwilling or unable to follow protocol requirements. 6. any condition which in the investigator's opinion deems the potential participant an unsuitable candidate to receive the study product. 7. received any interferons and any nasal/pharyngeal sprays within 7 days prior to screening. 8. received covid-19 vaccine within 14 days prior to screening 9. had previous confirmed sars-cov-2 infection \>96 hours prior to being screened for the study.

1. subjects with any of the following conditions that would impair their ability to participate reliably in the trial, or those who may increase the risk to themselves or others by participating 1. clinically significant laboratory abnormalities (including a screening test of aspartate aminotransferase/alanine aminotransferase (ast/alt) \> 5 times the upper limit of normal \[uln\] and/or estimated glomerular filtration rate \[egfr\] \< 30 ml/min/1.73m2) 2. serious medical illnesses (including known history of major hematological, renal, cardiovascular, or hepatic abnormalities that are clinically significant) 3. psychological condition or social circumstances 2. received an experimental medication within 1 month prior to screening or expect to receive such treatment during the study period. 3. with contraindication or hypersensitivity to the study product or any of its component. 4. pregnant or lactating women. 5. unwilling or unable to follow protocol requirements. 6. any condition which in the investigator's opinion deems the potential participant an unsuitable candidate to receive the study product. 7. received any interferons and any nasal/pharyngeal sprays within 7 days prior to screening. 8. received covid-19 vaccine within 14 days prior to screening 9. had previous confirmed sars-cov-2 infection \>96 hours prior to being screened for the study.

subjects with any of the following conditions that would impair their ability to participate reliably in the trial, or those who may increase the risk to themselves or others by participating clinically significant laboratory abnormalities (including a screening test of aspartate aminotransferase/alanine aminotransferase (ast/alt) > 5 times the upper limit of normal [uln] and/or estimated glomerular filtration rate [egfr] < 30 ml/min/1.73m2) serious medical illnesses (including known history of major hematological, renal, cardiovascular, or hepatic abnormalities that are clinically significant) psychological condition or social circumstances received an experimental medication within 1 month prior to screening or expect to receive such treatment during the study period. with contraindication or hypersensitivity to the study product or any of its component. pregnant or lactating women. unwilling or unable to follow protocol requirements. any condition which in the investigator's opinion deems the potential participant an unsuitable candidate to receive the study product. received any interferons and any nasal/pharyngeal sprays within 7 days prior to screening. received covid-19 vaccine within 14 days prior to screening had previous confirmed sars-cov-2 infection >96 hours prior to being screened for the study.

subjects with any of the following conditions that would impair their ability to participate reliably in the trial, or those who may increase the risk to themselves or others by participating clinically significant laboratory abnormalities (including a screening test of aspartate aminotransferase/alanine aminotransferase (ast/alt) > 5 times the upper limit of normal [uln] and/or estimated glomerular filtration rate [egfr] < 30 ml/min/1.73m2) serious medical illnesses (including known history of major hematological, renal, cardiovascular, or hepatic abnormalities that are clinically significant) psychological condition or social circumstances received an experimental medication within 1 month prior to screening or expect to receive such treatment during the study period. with contraindication or hypersensitivity to the study product or any of its component. pregnant or lactating women. unwilling or unable to follow protocol requirements. any condition which in the investigator's opinion deems the potential participant an unsuitable candidate to receive the study product. received any interferons and any nasal/pharyngeal sprays within 7 days prior to screening. received covid-19 vaccine within 14 days prior to screening had previous confirmed sars-cov-2 infection >96 hours prior to being screened for the study.